scholarly journals Bacteria and Host Interplay in Staphylococcus aureus Septic Arthritis and Sepsis

Pathogens ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 158
Author(s):  
Tao Jin ◽  
Majd Mohammad ◽  
Rille Pullerits ◽  
Abukar Ali
Keyword(s):  
Staphylococcus Aureus ◽  
Septic Arthritis ◽  
Virulence Factors ◽  
Early Time ◽  
Multiple Organ ◽  
Joint Disease ◽  
Immune Paralysis ◽  
Late Treatment ◽  
New Treatment ◽  
Treatment Alternatives

Staphylococcus aureus (S. aureus) infections are a major healthcare challenge and new treatment alternatives are needed. S. aureus septic arthritis, a debilitating joint disease, causes permanent joint dysfunction in almost 50% of the patients. S. aureus bacteremia is associated with higher mortalities than bacteremia caused by most other microbes and can develop to severe sepsis and death. The key to new therapies is understanding the interplay between bacterial virulence factors and host immune response, which decides the disease outcome. S. aureus produces numerous virulence factors that facilitate bacterial dissemination, invasion into joint cavity, and cause septic arthritis. Monocytes, activated by several components of S. aureus such as lipoproteins, are responsible for bone destructions. In S. aureus sepsis, cytokine storm induced by S. aureus components leads to the hyperinflammatory status, DIC, multiple organ failure, and later death. The immune suppressive therapies at the very early time point might be protective. However, the timing of treatment is crucial, as late treatment may aggravate the immune paralysis and lead to uncontrolled infection and death.

scholarly journals An 18 year clinical review of septic arthritis from tropical Australia

1996 ◽  
Vol 117 (3) ◽  
pp. 423-428 ◽  
Author(s):  
D. S. Morgan ◽  
D. Fisher ◽  
A. Merianos ◽  
B. J. Currie
Keyword(s):  
Staphylococcus Aureus ◽  
Septic Arthritis ◽  
Streptococcus Pyogenes ◽  
Needle Aspiration ◽  
Joint Disease ◽  
Medical Illness ◽  
Treatment Procedure ◽  
Aboriginal Australians ◽  
Tropical Australia ◽  
Open Arthrotomy

SummaryA retrospective study of 191 cases of septic arthritis was undertaken at Royal Darwin Hospital in the tropical north of Australia. Incidence was 9·2 per 100000 overall and 29·1 per 100000 in Aboriginal Australians (RR 6·6; 95% CI 5·0–8·9). Males were affected more than females (RR 1·6; 95% CI 1·2–2·1). There was no previous joint disease or medical illness in 54%. The commonest joints involved were the knee (54%) and hip (13%). Significant age associations were infected hips in those under 15 years and infected knees in those over 45 years. Seventy-two percent of infections were haematogenous. Causative organisms included Staphylococcus aureus (37%),Streptococcus pyogenes(16%) andNeisseria gonorrhoeae(12%). Unusual infections included three melioidosis cases. Polyarthritis occurred in 17%, withN. gonorrhoeae(11/23) more likely to present as polyarthritis than other organisms (22/168) (OR 6·0; 95% CI 2·1–16·7). Univariate and multivariate analysis showed the hip to be at greater risk forS. aureusthan other joints. Open arthrotomy was a more successful treatment procedure than arthroscopic washout or needle aspiration.

scholarly journals S. lugdunensis Native-Joint Septic Arthritis: Case Report and Review of the Literature

2017 ◽  
Vol 2017 ◽  
pp. 1-3
Author(s):  
C. Danielle Tan ◽  
Donna Moritz ◽  
Alfredo J. Mena Lora
Keyword(s):  
Staphylococcus Aureus ◽  
Case Report ◽  
Infective Endocarditis ◽  
Septic Arthritis ◽  
Clinical Disease ◽  
Joint Disease ◽  
Review Of The Literature ◽  
Medical Problems ◽  
Staphylococcus Lugdunensis

Staphylococcus lugdunensis is a skin commensal classified as a coagulase-negative Staphylococcus (CoNS). Though CoNS is typically associated with less aggressive clinical disease than Staphylococcus aureus, there is growing awareness that S. lugdunensis may be as virulent as S. aureus. The association between S. lugdunensis and infective endocarditis is well known, but few reports of native-joint disease with this organism exist. We report a case a 28-year-old male with no prior medical problems presenting with native-joint septic arthritis. Cultures grew S. lugdunensis. To our knowledge, this is the fifth case reported in the literature.

scholarly journals An unexpected diagnosis of methicillin-resistant Staphylococcus aureus septic arthritis.

2009 ◽  
Vol 1 (1) ◽  
pp. 13 ◽  
Author(s):  
Tanujan Thangarajah ◽  
Timothy J. Neal ◽  
Thomas D. Kennedy
Keyword(s):  
Staphylococcus Aureus ◽  
Septic Arthritis ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Asymptomatic Carrier ◽  
Joint Disease ◽  
Surrounding Soft Tissue ◽  
Methicillin Resistant ◽  
Delayed Treatment ◽  
First Case ◽  
Distal Interphalangeal

Hand infections can result in serious tissue damage and gross functional impairment. This is particularly true in the case of septic arthritis, the most destructive of all joint disease. We report the first case of methicillin-resistant Staphylococcus aureus septic arthritis of the distal interphalangeal joint to have occurred in a patient devoid of all risk factors traditionally associated with a hospital-associated infection (HA-MRSA). The afflicted patient’s only exposure to the pathogen was during her role as a community carer for an asymptomatic carrier. Delayed treatment allowed the infection to rapidly destroy surrounding soft tissue and necessitate in the need for arthrodesis. It is, therefore imperative that clinicians maintain a low index of suspicion for methicillin-resistant Staphylococcus aureus as the causative pathogen in similar cases. Consequently, consideration of empirical antibiotic therapy for this patient subgroup is discussed.

Cytochemical Studies of Cell Wall Biosynthesis in Staphylococcus Aureus

1972 ◽  
Vol 30 ◽  
pp. 328-329
Author(s):  
Masaatsu Koike ◽  
Koichi Nakashima ◽  
Kyoko Iida
Keyword(s):  
Staphylococcus Aureus ◽  
Periodate Oxidation ◽  
Early Time ◽  
The Other ◽  
Penicillin G ◽  
Cell Wall Biosynthesis ◽  
Septal Wall ◽  
Peptidoglycan Biosynthesis ◽  
Gram Positive Bacteria ◽  
Cross Linkage

Penicillin exerts the activity to inhibit the peptide cross linkage between each polysaccharide backbone at the final stage of wall-peptidoglycan biosynthesis of bacteria. Morphologically, alterations of the septal wall and mesosome in gram-positive bacteria, which were occurred in early time after treatment with penicillin, have been observed. In this experiment, these alterations were cytochemically investigated by means of silver-methenamine staining after periodate oxidation, which is applied for detection of localization of wall mucopolysaccharide.Staphylococcus aureus strain 209P treated with 100 u/ml of penicillin G was divided into two aliquotes. One was fixed by Kellenberger-Ryter's OSO4 fixative at 30, 60 and 120 min after addition of the antibiotic, dehydrated through alcohol series, and embedded in Epon 812 (Specimen A). The other was fixed by 21 glutaraldehyde, dehydrated through glycolmethacrylate series and embedded in glycolmethacrylate mixture, according to Bernhard's method (Specimen B).

scholarly journals High-dose diquat poisoning: a case report

2021 ◽  
Vol 49 (6) ◽  
pp. 030006052110261
Author(s):  
Yanxia Huang ◽  
Renjing Zhang ◽  
Mei Meng ◽  
Dechang Chen ◽  
Yunxin Deng
Keyword(s):  
Renal Failure ◽  
Multiple Organ Failure ◽  
Organ Failure ◽  
Multiple Organ ◽  
High Dose ◽  
Severe Respiratory Failure ◽  
Aggressive Treatment ◽  
Lung Lesions ◽  
Pulmonary Lesions ◽  
New Treatment

Diquat is a widely used herbicide that is substituted for paraquat. With paraquat off the market, cases of diquat poisoning have been gradually increasing. The kidney is the most frequently impaired organ in diquat poisoning. Few cases of multiple organ failure caused by diquat have been reported. We herein describe a 30-year-old man who orally ingested about 160 mL of enriched diquat. Despite aggressive treatment, the patient’s condition progressed to multiple organ failure and death. The pulmonary lesions in this patient were different from those previously reported. This patient did not die of renal failure but of severe respiratory failure. He exhibited three different stages of pulmonary disease. The lung lesions in this case were unique. We hope that doctors will pay more attention to the lung lesions in patients with diquat poisoning in future and find new treatment methods to save the lives of such patients.

scholarly journals 1202. Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S622-S623
Author(s):  
Alisa W Serio ◽  
S Ken Tanaka ◽  
Kelly Wright ◽  
Lynne Garrity-Ryan
Keyword(s):  
Staphylococcus Aureus ◽  
Protein Synthesis ◽  
Virulence Factors ◽  
Hemolytic Activity ◽  
Protein Biosynthesis ◽  
The United States ◽  
Aureus Strain ◽  
Protein Synthesis Inhibitors ◽  
Subinhibitory Concentrations

Abstract Background In animal models of Staphylococcus aureus infection, α-hemolysin has been shown to be a key virulence factor. Treatment of S. aureus with subinhibitory levels of protein synthesis inhibitors can decrease α-hemolysin expression. Omadacycline, a novel aminomethylcycline antibiotic in the tetracycline class of bacterial protein biosynthesis inhibitors, is approved in the United States for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults. This study was performed to determine the durability of inhibition and effect of subinhibitory concentrations of omadacycline on S. aureus hemolytic activity. Methods All experiments used the methicillin-sensitive S. aureus strain Wood 46 (ATCC 10832), a laboratory strain known to secrete high levels of α-hemolysin. Minimum inhibitory concentrations (MICs) of omadacycline and comparator antibiotics (tetracycline, cephalothin, clindamycin, vancomycin, linezolid) were determined. Growth of S. aureus with all antibiotics was determined and the percentage of hemolysis assayed. “Washout” experiments were performed with omadacycline only. Results S. aureus cultures treated with 1/2 or 1/4 the MIC of omadacycline for 4 hours showed hemolysis units/108 CFU of 47% and 59% of vehicle-treated cultures, respectively (Fig. 1A, 1B). In washout experiments, treatment with as little as 1/4 the MIC of omadacycline for 1 hour decreased the hemolysis units/108 CFU by 60% for 4 hours following removal of the drug (Table 1). Figure 1 Table 1 Conclusion Omadacycline inhibited S. aureus hemolytic activity in vitro at subinhibitory concentrations and inhibition was maintained for ≥ 4 hours after removal of extracellular drug (Fig. 2). The suppression of virulence factors throughout the approved omadacycline dosing interval, in addition to the in vitro potency of omadacycline, may contribute to the efficacy of omadacycline for ABSSSI and CABP due to virulent S. aureus. This finding may apply to other organisms and other virulence factors that require new protein synthesis to establish disease. Figure 2 Disclosures Alisa W. Serio, PhD, Paratek Pharmaceuticals, Inc. (Employee, Shareholder) S. Ken Tanaka, PhD, Paratek Pharmaceuticals, Inc. (Employee, Shareholder) Kelly Wright, PharmD, Paratek Pharmaceuticals, Inc. (Employee, Shareholder) Lynne Garrity-Ryan, PhD, Paratek Pharmaceuticals, Inc. (Employee, Shareholder)

Matrix metalloproteinase-9 (gelatinase B) deficiency leads to increased severity of Staphylococcus aureus-triggered septic arthritis

2006 ◽  
Vol 8 (6) ◽  
pp. 1434-1439 ◽  
Author(s):  
Ann-Marie Calander ◽  
Sofie Starckx ◽  
Ghislain Opdenakker ◽  
Philip Bergin ◽  
Marianne Quiding-Järbrink ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Matrix Metalloproteinase ◽  
Septic Arthritis ◽  
Matrix Metalloproteinase 9 ◽  
Gelatinase B ◽  
Metalloproteinase 9

scholarly journals Phosphorylation of MgrA and Its Effect on Expression of the NorA and NorB Efflux Pumps of Staphylococcus aureus

2010 ◽  
Vol 192 (10) ◽  
pp. 2525-2534 ◽  
Author(s):  
Que Chi Truong-Bolduc ◽  
David C. Hooper
Keyword(s):  
Staphylococcus Aureus ◽  
Multidrug Resistance ◽  
Virulence Factors ◽  
Double Mutant ◽  
Efflux Pumps ◽  
Efflux Transporters ◽  
Global Regulator ◽  
Binding Assays ◽  
Genes Encoding ◽  
Gel Shift

ABSTRACT MgrA is a global regulator in Staphylococcus aureus that controls the expression of diverse genes encoding virulence factors and multidrug resistance (MDR) efflux transporters. We identified pknB, which encodes the (Ser/Thr) kinase PknB, in the S. aureus genome. PknB was able to autophosphorylate as well as phosphorylate purified MgrA. We demonstrated that rsbU, which encodes a Ser/Thr phosphatase and is involved in the activation of the SigB regulon, was able to dephosphorylate MgrA-P but not PknB-P. Serines 110 and 113 of MgrA were found to be phosphorylated, and Ala substitutions at these positions resulted in reductions in the level of phosphorylation of MgrA. DNA gel shift binding assays using norA and norB promoters showed that MgrA-P was able to bind the norB promoter but not the norA promoter, a pattern which was the reverse of that for unphosphorylated MgrA. The double mutant MgrAS110A-S113A bound to the norA promoter but not the norB promoter. The double mutant led to a 2-fold decrease in norA transcripts and a 2-fold decrease in the MICs of norfloxacin and ciprofloxacin in strain RN6390. Thus, phosphorylation of MgrA results in loss of binding to the norA promoter, but with a gain of the ability to bind the norB promoter. Loss of the ability to phosphorylate MgrA by Ala substitution resulted in increased repression of norA expression and in reductions in susceptibilities to NorA substrates.

New Strategies Targeting Virulence Factors of Staphylococcus aureus and Pseudomonas aeruginosa

2017 ◽  
Vol 38 (03) ◽  
pp. 346-358 ◽  
Author(s):  
Bruno François ◽  
Charles-Edouard Luyt ◽  
C. Stover ◽  
Jeffery Brubaker ◽  
Jean Chastre ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Pseudomonas Aeruginosa ◽  
Virulence Factors ◽  
Effective Utilization ◽  
Mechanically Ventilated ◽  
Stage Of Development ◽  
Antivirulence Agents ◽  
Interventional Therapies ◽  
Improve Patient ◽  
New Strategies

AbstractMorbidity, mortality, and economic burden of nosocomial pneumonia caused by Staphylococcus aureus and Pseudomonas aeruginosa remain high in mechanically ventilated and hospitalized patients despite the use of empirical antibiotic therapy or antibiotics against specific classes of pathogens and procedures to reduce nosocomial infections in hospital settings. Newer agents that neutralize or inhibit specific S. aureus or P. aeruginosa virulence factors may eliminate or reduce the risk for developing pneumonia before or during mechanical ventilation and may improve patient outcomes through mechanisms that differ from those of antibiotics. In this article, we review the types, mechanisms of action, potential advantages, and stage of development of antivirulence agents (AVAs) that hold promise as alternative preventive or interventional therapies against S. aureus– and P. aeruginosa–associated nosocomial pneumonias. We also present and discuss challenges to the effective utilization of AVAs separately from or in addition to antibiotics and the design of clinical trials and meaningful study end points.

Virulence Factors of Staphylococcus aureus in the Pathogenesis of Endocarditis A Comparative Study of Clinical Isolates

1998 ◽  
Vol 287 (4) ◽  
pp. 433-447 ◽  
Author(s):  
Shahin Nozohoor ◽  
Anders Heimdahl ◽  
Patricia Colque-Navarro ◽  
Inger Julander ◽  
Bo Söderquist ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Comparative Study ◽  
Virulence Factors ◽  
Clinical Isolates
Sign in / Sign up

Export Citation Format

Share Document